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Abstract
OBJECTIVE: To determine the effects of Yishenji-
angzhuo granules (YJG) on bone metabolism and
to explore the changes in levels of bone Gla protein
(BGP), tartrate-resistant acid phosphatase (TRAP),
as well as their relationships with levels of B cells,
regulatory T cells (Treg) and interleukin (IL)-17 in
patients with stage 3-4 chronic kidney disease
(CKD) before and after treatment.
METHODS: Fifty-three stage 3-4 CKD patients were
divided randomly into two groups: YJG treatment
and control. Peripheral blood was taken from two
groups of CKD patients and 21 healthy subjects in
the normal group. The parameters determined
were the levels of CD4+ , CD19+ , CD19+CD69+ ,
CD19+AV, Treg (CD4+CD25+CD127lo), BGP, TRAP,
IL-17, calcium, phosphate, blood urea nitrogen, se-
rum creatinine (SCr), hemoglobin (Hb) in peripheral
blood, and urinary creatinine. Calcium-phosphate
products and endogenous creatinine clearance
rate (CCr) were calculated according to standard
protocols.
RESULTS: In YJG and control groups, SCr levels
were lowered (P<0.01) after treatment, whereas
CCr (P<0.05) as well as Hb and albumin levels (P<
0.01) were increased. The changes in levels of CCr
and SCr in the YJG group were more significant. Af-
ter treatment, CD19+CD69+ and Treg levels in the
two groups varied (P<0.01) compared with those of
the normal group; the level of CD19+ increased but
the levels of CD4 + and CD19 + AV decreased (P<
0.01) in both groups. Compared with the control
group, the changes of CD19+ and CD19+AV in the
YJG group were more apparent (P<0.05). Com-
pared with the normal group, levels of IL-17 in both
groups increased significantly (P<0.01), and the dif-
ference in the control group was more significant
(P<0.05). After treatment, the TRAP level increased
(P<0.05), but the difference in BGP level (P>0.05)
was not significant.
CONCLUSION: In stage 3-4 CKD patients, B cells
and IL-17 participated in the induction of osteo-
clast activation. YJG could also elevate the level of B
cells and decrease their apoptosis, but showed no
significant effects on active B cells, IL-17 or osteo-
clast activity.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Renal osteodystrophy is a disease related to defects in
bone metabolism. It is caused by chronic renal failure.
In general, it is recognized to be related to hyperphos-
phatemia, decreased production of 1ɑ, 25-Dihydroxyvi-
tamin D3 [1ɑ,25-(OH)2D3] and secondary hyperpara-
thyroidism. Owing to the influence of urotoxin, sub-
jects with stage 3-4 chronic kidney disease (CKD) usu-
ally have immune dysfunction. Immune cells and bone
cells are closely related not only with regard to com-
mon origin, but also in mediation of the differentia-
tion of bone cells by immune cells through the recep-
tor activator for nuclear factor-kappa B/receptor activa-
tor for nuclear factor-kappa B ligand/osteoprotegerin
(RANK/RANKL/OPG) system. Activated B cells pro-
duce RANKL, and induce osteoclast activation.1 Inter-
leukin (IL)-17 can upregulate RANKL expression, in-
crease the binding ratio of RANKL/RANK, and in-
duce osteoclast activation.2 Regulatory T cells suppress
osteoclast generation through cytolytic T lympho-
cyte-associated antigen (CTLA)-4.3
The Traditional Chinese Medicine (TCM) Yishenjiang-
zhuo granules (YJG) can strengthen the spleen and
tonify the kidney, stop stasis and decrease turbidity.
Hence, it could suppress osteoclast activation by invigo-
rating the kidney and activating the blood circulation.
Bone metabolism can be determined by measuring lev-
els of bone Gla protein (BGP) and tartrate-resistant ac-
id phosphatase (TRAP), as well as the indices of bone
formation and bone resorption.
In the present study, we explored whether YJG could
regulate bone metabolism through immunity using
flow cytometry to detect CD4 + , CD19 + , CD19 +
CD69 + , CD19 + AV and regulatory T cells (Treg)
(CD4 + CD25 + CD127lo) cells, and using an en-
zyme-linked immunosorbent assay (ELISA) to detect
levels of BGP, TRAP, and IL-17 in peripheral blood.
METHODS
The study protocol was approved by the Medical Eth-
ics Committee of Fujian Provincial People's Hospital
(Fujian, China). All patients provided written in-
formed consent.
Subjects
The 53 cases who formed the study cohort had stage
3-4 CKD and were inpatients or outpatients from the
Department of Nephropathy of Fujian Provincial Peo-
ple's Hospital from March 2008 to July 2009. They
were divided randomly into two groups by random
number table method. There were 31 cases [15 males;
age range, 40-79 years (mean, 59 ± 11 years)] in the
YJG treatment group (19 had chronic glomerulone-
phritis, four had diabetic nephropathy (DN) and eight
had hypertension renal disease). There were 22 cases
[10 males; age range, 44-74 years (mean, 60±11 years)]
in the control group (Twelve had chronic glomerulone-
phritis, four had DN, and six had hypertension with re-
nal disease). In addition, a normal group of 21 healthy
volunteers [six males; age range, 20-65 years (mean,
57±5 years)] was established. There were no significant
differences in general demographics between the
groups (P>0.05).
Diagnostic criteria
The diagnostic criteria for CKD were based on the
Clinical Practice Guidelines for Chronic Kidney Dis-
ease (2002) set by the National Kidney Foundation.4
Diagnosis and classification based on TCM
The main syndrome was spleen and kidney deficiency
syndrome. The criteria for differentiating the syn-
drome in the literature5 involve having two main symp-
toms, or one main symptom with two secondary symp-
toms. The main symptoms were lumbar debility; lan-
guidness, persistent edema, anorexia and abdominal
distention. The secondary symptoms were aversion to
cold, cold limbs, cool and frequent nocturia, loose
stools, purple tongue, and deep/slow pulse.
The accompanying syndromes were damp pathogen
syndrome with symptoms of nausea and vomiting; dry
mouth with bitter taste; anorexia and abdominal dis-
tention; dry stools; oliguria; yellow and thick greasy
tongue fur; and slippery pulse.
Inclusion and exclusion criteria
Stage 3-4 CKD was diagnosed using the criteria de-
tailed above. The exclusion criteria were patients who
had undergone surgery; who had infections or tumors
in the month before study enrolment; with CKD
caused by connective-tissue diseases such as systemic lu-
pus erythematosus and Sjögren's syndrome; with acute
renal failure; undergoing treatment with anti-inflamma-
tory drugs, antioxidants or aspirin; presenting with fac-
tors that cause reversible decline of kidney function in
a short time (uncontrolled hypertension, severe infec-
tion, trauma, drugs that may cause kidney injury, and
decrease in the volume of circulating blood).
Treatments
The YJG treatment group and control group were treat-
ed with caltrate (0.6 g/day; Suzhou Wyeth Nutritional
Co., Ltd., Suzhou, China) and alfacalcidol (0.5 mg/
day; Kunming Baker Norton Pharmaceutical Co.,
Ltd., Kunming, China).
For the control group, the acid-base balance and elec-
trolyte balance was adjusted. A high-quality, low-pro-
tein and high-calorie diet (containing essential amino
acids) was given. Subjects with hypertensive renal dis-
ease were given an angiotensin-converting enzyme in-
hibitor [Angiotensin-Converting Enzyme Inhibitors
(ACEI); lotensin; Beijing Novartis Pharmaceutical Co.,
Ltd., Beijing, China] or angiotensin receptor blocker
(ARB; valsartan; Beijing Novartis Pharmaceutical Co.,
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Ltd.) if the serum creatinine (SCr) was <265 µmoL/L,
or a calcium-channel blocker (CCB; felodipine sus-
tained-release tablets; Shanghai AstraZeneca Pharmaceu-
tical Co., Ltd., Shanghai, China) if SCr>265 µmoL/L.
Other classes of antihypertensive drugs (ACEI, ARB or
CCB) were added according to blood-pressure read-
ings. Subjects with edema (urine <2000 mL) were giv-
en furosemide (Shanghai Meiyou Pharmaceutical Co.,
Ltd., Shanghai, China). Subjects with renal anemia pa-
tients were given erythropoietin (EPO; Epiao; Sheng-
yang Sansheng Co., Ltd., Shenyang, China).
For the YJG treatment group, in addition to the medi-
cations detailed above and used in the control group,
Yishenjiangzhuo granules (Preparation Section, Fujian
Provincial People's Hospital) was given (10 g, t.d.s., p.
o.) 30 min after each meal. The ingredients of each
YJG were: Taizishen (Radix Pseudostellariae) 15 g; Ful-
ing (Poria) 15 g; Baizhu (Rhizoma Atractylodis Macro-
cephalae) 10 g; Huangqi (Radix Astragali Mongolici)
15 g; Sangjisheng (Herba Taxilli Chinensis) 15 g; Sang-
shen (Fructus Mori) 12 g; Dahuang (Radix et Rhizoma
Rhei Palm) 6 g; Liuyuexue (Herba Serissae Japonicae)
15 g; Danshen (Radix Salviae Miltiorrhizae) 15 g;
Cheqianzi (Semen Plantaginis) 15 g; Danggui (Radix
Angelicae Sinensis) 6 g; Yimucao (Herba Leonuri Japoni-
ci) 15 g; Huainiuxi (Radix Achyranthis Bidentatae)
15 g; and Chenpi (Pericarpium Citri Reticulatae) 6 g.
These ingredients were water-extracted for 1.5 h twice,
alcohol-extracted into a thick paste, added to dextrin,
sugar-granulated, and dried. Normal group did not re-
ceive treatment.
Assays
Blood samples were taken in the morning and analyzed
within 1 h. Plasma was preserved at － 20℃ for en-
zyme-linked immunosorbent assay (ELISA) analyses.
ELISA kits were purchased from Becton Dickinson
Biosciences (San Jose, CA, USA).
Levels of CD4+, CD19+, CD19+CD69+, CD19+AV,
and Treg (CD4+CD25+CD127lo) in peripheral blood
were analyzed by flow cytometry, as described previous-
ly.6 Levels of BGP, TRAP and IL-17 in peripheral blood
were analyzed by double-antibody sandwich ELISA.
Blood levels of calcium (Ca), phosphate (P), and blood
urea nitrogen (BUN), as well as SCr levels, were deter-
mined using an Automatic Biochemical Analyzer
(Beckman Coulter, Fullerton, CA, USA). The urinary
content of creatinine was measured by reverse-phase
high-performance liquid chromatography (American
Waster, Inc.). Hemoglobin (Hb) content was deter-
mined using a Hemo-analyzer (Beckman Coulter). The
product of calcium-phosphate (Ca×P) was determined
according to the blood contents of calcium and phos-
phate. The clearance rate of endogenous creatinine
(CCr) was calculated according to the values of BUN
and SCr.
Statistical analyses
Data were analyzed using SPSS ver13.0 (SPSS, Chica-
go, IL, USA). The data of levels of CD4+ , CD19+ ,
CD19+CD69+ , CD19+AV, CD4+CD25+CD127lo,
BGP, and TRAP did not follow a normal distribution,
so rank correlation analyses were used to assess the sig-
nificance of the results. Data are expressed as xˉ ±s, and
Spearman's rank-order correlation used for correlation
analyses. P<0.05 was considered statistically significant.
RESULTS
Changes in levels of BUN, albumin (Alb) and Hb as
well as SCrandCCrbefore andafter treatment
After treatment, the level of BUN showed no signifi-
cant change in the YJG treatment group and control
group (P<0.05). The level of SCr in both groups de-
creased (P<0.01), whereas levels of Hb and Alb in-
creased (P<0.05), as did the CCr (P<0.01). Compared
with the control group, the changes in SCr and CCr in
the YJG treatment group were more apparent (P<
0.05). Significant differences were found in the SCr
and CCr as well as levels of BUN, Alb, and Hb in the
normal group as compared with the YJG group and
control group (Table 1).
Changes in levels of CD19+, CD19+CD69+, CD19+
AV, CD4+Treg, and IL-17 before and after treatment
After treatment, the levels of CD19+CD69+ and Treg
Group
YJG
Control
Normal
n
31
22
21
Period
Pre-treatment
Post-treatment
Pre-treatment
Post-treatment
-
SCr (μmoL/L)
310.7±92.6
276.1±101.5ad
317.5±71.0
300.7±75.2b
67.5±13.2c
BUN (mmoL/L)
14.8±5.6
15.6±6.7
14.6±5.4
16.6±6.4
5.7±1.4c
CCr (mL/min)
25.61±8.83
33.4±12.4ad
25.7±6.0
29.1±6.9b
96.3±10.4c
Hb (g/L)
90.9±9.1
105.9±10.5b
87.7±12.7
98.8±11.5b
145.3±9.4c
Alb (g/L)
35.0±6.3
37.4±5.2b
35.1±6.6
36.6±4.8b
51.0±5.6c
Notes: YJG group were treated with caltrate (0.6 g/day), alfacalcidol (0.5 mg/day) and Yishenjiangzhuo granules (10 g, t.d.s., p.o.). Control
group were treated with caltrate (0.6 g/day), alfacalcidol (0.5 mg/day) and Symptomatic treatment. Normal group did not receive treat-
ment. SCr: serum creatinine; Hb: hemoglobin; CCr: creatinine clearance rate; BUN: blood urea nitrogen; Alb: albumin. Compared with
pre-treatment, aP<0.01, bP<0.05; compared with the YJG treatment and control groups cP<0.05; compared with the control group, dP<0.05.
Table 1 Changes in levels of BUN, Alb and Hb as well as SCr and CCr before and after treatment ( xˉ ±s)
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in the YJG and control groups showed no significant
change (P>0.05). Compared with the normal group,
the level of Treg in the YJG and control groups was
lower (P<0.01), and the level of CD19+CD69+ was
higher (P<0.01) (Table 2).
After treatment, in the YJG and control groups, the lev-
el of CD19+ increased, CD4+ declined, and CD19+
AV decreased (P<0.01). Compared with the control
group, the changes in levels of CD19+ and CD19+ AV
were more significant in the YJG group (P<0.05) (Ta-
ble 2).
Compared with the normal group, the levels of IL-17
in the YJG and control groups were higher (P<0.01).
After treatment, the level of IL-17 in the YJG group
showed no significant change (P>0.05), whereas the
level of IL-17 in the control group was higher (P<
0.05) (Table 2).
Changes in levels of P, Ca×P, BGP and TRAP before
and after treatment
After treatment, no significant change was found in
the levels of P or Ca×P in YJG and control groups (P>
0.05). The TRAP level increased (P<0.05), but the
BGP level showed no noticeable change (P>0.05) in ei-
ther group. Significant differences were found in levels
of BGP and TRAP in the YJG and control groups as
compared with the normal group (P<0.05) (Table 3).
Correlations were found between levels of CD19+ and
TRAP (r=－0.333, P<0.05), CCr and CD19+AV (r=
0.380, P<0.01); CCr and SCr (r=－ 0.787, P<0.01);
Ca × P and BUN (r=0.456, P<0.01); and CD19 +AV
and IL-17 (r=0.316, P<0.05) (Table 3).
DISCUSSION
The RANK/RANKL/OPG system is an important sig-
nal transduction pathway for osteoclast differentiation.
RANKL can act on RANK on the osteoclast cell mem-
brane and its pseudo-receptor OPG.7 OPG and
RANKL are produced by osteoblasts. RANKL com-
bined with RANK can induce the osteoclast differentia-
tion.8 Therefore, OPG, RANK and RANKL partici-
pate together in the interaction between osteoblasts
and osteoclasts, and maintain the physiological balance
of bone metabolism.
BGP is secreted by matures osteoblasts. The changes of
BGP levels in serum may reflect osteoblast activity.
The TRAP level in osteoclasts is taken to be a specific
index of osteoclast activity in renal osteodystrophy.9
The generation and differentiation of osteoclasts are
controlled by the RANK/RANKL/OPG system.
RANKL promotes the formation, differentiation and
maturity of osteoclasts, and inhibits their apoptosis.
B-lymphocytes differentiate from lymphoid stem cells
in the bone marrow, and regulate humoral immunity
by generating antibodies. Activated B-lymphocytes pro-
mote the differentiation and activation of osteoclasts,
secrete RANKL, IL-6 and tumor necrosis factor
Group
YJG
Control
Normal
n
31
22
21
Period
Pre-treatment
Post-treatment
Pre-treatment
Post-treatment
-
P (mmoL/L)
1.47±0.26
1.51±0.25
1.48±0.36
1.54±0.33
1.34±0.18
Ca×P
40.48±7.91
42.53±8.37
40.66±8.20
43.07±5.19
41.67±5.56
BGP (ng/L)
7.43±6.47
7.51±3.63
8.12±3.49
8.67±4.21
3.65±1.42a
TRAP (ng/L)
74.68±70.80
94.96±61.32b
65.05±33.84
89.90±29.26b
32.04±8.13a
Table 3 Changes in levels of P, Ca×P, BGP and TRAP before and after treatment ( xˉ ±s)
Notes: YJG group were treated with caltrate (0.6 g/day), alfacalcidol (0.5 mg/day) and Yishenjiangzhuo granules (YJG) (10 g, t.d.s., p.o.).
Control group were treated with caltrate (0.6 g/day), alfacalcidol (0.5 mg/day) and Symptomatic treatment. Normal group did not receive
treatment. P: Phosphate; Ca×P: calcium-phosphate; BGP: bone Gla protein; TRAP: tartrate-resistant acid phosphatase; Compared with
the YJG and control groups, aP<0.05; compared with pre-treatment, bP<0.01.
Group
YSJZ
Control
Normal
n
31
22
21
Period
Pre-treatment
Post-treatment
Pre-treatment
Post-treatment
-
CD19+(%)
9.8±7.4
19.3±9.0abc
9.0±3.9
13.0±5.1ab
9.1±4.6
CD19+CD69+(%)
4.9±3.2
6.1±4.6b
5.3±3.2
6.6±3.6b
2.5±1.0
CD19+AV (%)
8.4±3.3
5.0±2.4ac
9.1±1.9
7.1±1.9a
4.6±0.9
Treg (%)
6.5±2.0
7.4±1.4b
7.3±3.5
7.7±3.8b
8.8±3.0
CD4+ (%)
35.2±15.1
26.7±10.4a
29.1±18.5
25.7±11.8a
29.5±10.8
IL-17 (ng/L)
39.9±31.5
41.5±30.4
36.1±15.0
44.6±15.1d
1.9±1.1
Notes: YJG group were treated with caltrate (0.6 g/day), alfacalcidol (0.5 mg/day) and Yishenjiangzhuo granules (YJG) (10 g, t.d.s., p.o.).
Control group were treated with caltrate (0.6 g/day), alfacalcidol (0.5 mg/day) and symptomatic treatment. Normal group did not receive
treatment. Treg: regulatory T cells; IL-17: interleukin-17. Compared with pre-treatment therapy, aP<0.01, dP<0.05; compared with the con-
trol group, cP<0.05; compared with the normal group, bP<0.01.
Table 2 Changes in levels of CD19+, CD19+CD69+, CD19+AV, CD4+ Treg, and IL-17 before and after treatment ( xˉ ±s)
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(TNF)-ɑ, and promote osteoclast activity. Activated
B-lymphocytes also express macrophage inflammatory
protein-1ɑ and human monocyte chemoattractant pro-
tein-3, which promote the migration and differentia-
tion of osteoclasts.10 IL-17 is a cytokine secreted by ac-
tive CD4 + T lymphocytes upon development of in-
flammation and autoimmune responses. It can up-regu-
late the expression of RANKL in osteoblasts.11 The
combination of RANK and RANKL can activate osteo-
clasts by various signal transduction pathways, and pro-
mote bone resorption. Treg are a group of dedicated
immunosuppression cells. Wang et al 12 reported that
Treg can inhibit B-lymphocytes by direct cell-to-cell
contact, with transforming growth factor-β1 and CT-
LA-4 being involved in this process. In addition, Treg
can also inhibit osteoclast formation through cell con-
tact mediated by CTLA-4.3
According to TCM theory, the pathogenesis of CKD is
due to dysfunction of the lung, spleen and kidney as
well as the failure in transportation of Qi through the
triple energizer (TE), with spleen and kidney deficien-
cy presented throughout the entire process. The kidney
governs bone and produces marrow, whereas the spleen
is the source of Qi and blood. Spleen and kidney defi-
ciency syndrome can cause Qi deficiency, leading to
blood stasis, which obstructs the microcirculation of or-
gans. This phenomenon is unfavorable for cells to
transport substances, and eventually induces disorders
of the growth and development of bone. Among the in-
gredients of YJG, Huangqi (Radix Astragali Mongolici),
Taizishen (Radix Pseudostellariae), Fuling (Poria) and
Baizhu (Rhizoma Atractylodis Macrocephalae) can
strengthen the spleen and replenish Qi. Also, Sangjish-
eng (Herba Taxilli Chinensis) and Sangshen (Fructus
Mori) can nourish the kidney. Liuyuexue (Herba Seris-
sae Japonicae), Dahuang (Radix et Rhizoma Rhei Palm)
and Cheqianzi (Semen Plantaginis) are used for resolv-
ing turbidity and eliminating dampness. Danshen (Ra-
dix Salviae Miltiorrhizae), Danggui (Radix Angelicae Si-
nensis) and Huainiuxi (Radix Achyranthis Bidentatae)
promote blood circulation. Chenpi (Pericarpium Citri
Reticulatae) strengthens the spleen and regulates Qi so
as to promote transportation of substances.
It has been reported that the separate use of Sangjish-
eng (Herba Taxilli Chinensis), Sangshen (Fructus Mori),
Huangqi (Radix Astragali Mongolici) and Dahuang (Ra-
dix et Rhizoma Rhei Palm) can inhibit osteoclast activi-
ty. 13 In the present study, a significant reduction in SCr
in CKD patients was found after YJG treatment (P<
0.01). The CCr in the YJG group was higher than that
in the control group (P<0.05). The levels of CD19 +
and CD19+CD69+ in patients with stage 3-4 CKD
were obviously higher than those in the normal group
(P<0.01). The level of CD19+CD69+ in the YJG and
control groups showed no significant change after treat-
ment (P>0.05). After treatment, in the YJG and con-
trol groups, the level of CD19 + increased (P<0.01),
the level of CD19 + -AV decreased (P<0.05), and the
level of CD19+ -AV in the YJG group declined more
obviously (P<0.05). These results suggested that YJG
could delay the progression of CKD and provide pro-
tection for uremic patients; and that the humoral im-
mune system of patients with stage 3-4 CKD is persis-
tently activated, even after treatment. YJG could more
obviously enhance the levels of B cells and inhibit
apoptosis in CKD patients than in the control group .
No significant change was found in CD19+CD69+ lev-
els in the YJG and control groups after treatment. Al-
though YJG could increase the number of B cells in
CKD patients and inhibit apoptosis, it had no signifi-
cant influence on active B cells, and humoral immuni-
ty in CKD patients continued to be activated after
treatment. The TRAP level in the YJG group increased
after treatment (P<0.05), suggesting that YJG could
not inhibit the activity of osteoblasts by invigorating
the spleen and kidney.
Levels of inflammatory factors such as high-sensitivity
C-reactive protein (hs-CRP) and IL-6 in CKD patients
are obviously higher than in healthy subjects, a fact
that is closely related to the progression of CKD.14 Lev-
els of CD4+ T cells in CKD patients in YJG and con-
trol groups continued to decrease after treatment (P<
0.01), whereas the levels of IL-17 in YJG and control
groups were obviously higher than those in the normal
group (P<0.01), and did not decline after treatment.
Additionally, the number and levels of Treg in YJG and
control groups were lower than those of the normal
group, and were still lower than the normal group after
treatment (P<0.05). These data suggested that CD4+
T cells in stage 3-4 CKD patients were differentiating
into Th17 cells and promoted the progression of mi-
cro-inflammation. YJG could not prevent the number
of IL-17 cells from increasing, and the immune system
was being activated persistently. Immune function
seems to be overactive with the progression of micro-in-
flammation.15 Before treatment, the following parame-
ters were correlated: CCr with CD19+AV (r=0.380, P<
0.01); Ccr with SCr (r=-0.787, P<0.01); CD19 + AV
with IL-17 (r=0.316, P<0.05); and CD19 + with
TRAP (r=-0.333, P<0.05). These data were consistent
with the fact that the CCr in stage 3-4 CKD patients
decreased, inflammation factors increased, and the im-
mune system was persistently activated, thereby giving
rise to bone loss.
The level of bone metabolism is dependent on the equi-
librium between the formation and resorption of bone.
In stage 3-4 CKD patients, osteoclasts can be activated
by hyperphosphatemia, secondary hyperparathyroid-
ism caused by a decrease in 1ɑ, 25-(OH)2D3 levels, and
activation of the immune system due to persistent mi-
cro-inflammation.16 Non-immune factors, i.e., increas-
es in levels of parathyroid hormone and decreases in
levels of 1ɑ,25-(OH)2D3 working through osteoblasts,
may also influence osteoclast activity, resulting in renal
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osteodystrophy. The level of BGP in YJG and control
groups showed no significant change after treatment
(P>0.05), indicating that osteoblast activity had no sig-
nificant change on osteoclast activation in stage 3-4
CKD patients. However, the level of TRAP increased
(P<0.05) in both groups after treatment. This finding
suggested that, with micro-inflammation in the im-
mune system of stage 3-4 CKD patients, the decrease
in the number of Treg cells downregulated the inhibi-
tion of B cells and TH17 cells, leading to an increase
in B-cell activation and a decrease of their apoptosis,
and considerable secretion of IL-17. The osteoblast ac-
tivation pathway was then activated by active B cells
and IL-17 cells, and the level of TRAP increased. The
difference in TRAP levels between YJG and control
groups was not significant after treatment, suggesting
that multiple factors of bone destruction may exist in
stage 3-4 CKD patients. The fact that YJG could not
delay activation of osteoclasts might be related to per-
sistent activation of osteoclasts by micro-inflammation
in CKD patients.
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